

Pharmaceutical company request for oral testimony at the May 15,2020
Idaho Medicaid Pharmacy & Therapeutics Committee meeting.

Submission # _04

Date request was received: 04/20/2020

Drug: Sublocade - indivior

Therapeutic Drug Class: Opioid Use Disorder

Pharmaceutical Company: Indivior

This request for oral testimony has been reviewed.

approved

From: Ng, Valerie <valerie.ng@Indivior.com>
Sent: Monday, April 20, 2020 12:27 PM
To: Eide, Tamara J. <Tamara.Eide@dhw.idaho.gov>
Subject: May 15, 2020, P&T Meeting [External Email]

Dear Dr. Eide:

Please find attached documents relative to new information/publication on Sublocade for review prior to the May 15th P&T meeting.

Prescribing Information of Sublocade was last updated in February 2020 – with new information on warnings and precautions, in addition to the recommended dosing.

A few weeks ago, RECOVER 12-month study outcomes was published in the Journal of Addiction Medicine. The full pdf version can be downloaded at no cost by clicking on “download” on the left-hand side through the following link:

[Recovery From Opioid Use Disorder \(OUD\) After Monthly Long-acting Buprenorphine Treatment](#)

I look forward to having the opportunity to share these information with you and the committee on May 15th.

Thank you,

Val

Valerie D. Ng, PharmD, MSIA, MT
Medical Outcomes & Value Liaison
Medical Affairs, North America

M (682) 718-1806
Valerie.Ng@indivior.com

Indivior Inc.
[10710 Midlothian Turnpike](#)
[Suite 430](#)
[North Chesterfield, VA 23235](#)
Indivior.com